Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas
Open Access
- 1 January 2019
- journal article
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 20 (1), 73-79
- https://doi.org/10.31557/apjcp.2019.20.1.73
Abstract
Background: Patients primarily received tamoxifen based on their menopausal status due to the lack ofimmunohistochemistry. A recent study has shown that hormonal receptors were not correlated with menopausal status,and thus, indicating that they present limited therapeutic and prognostic significance in breast cancer management.This study aimed to evaluate Ki-67 value and analyze its association with clinicopathologic parameters in breast cancerpatients. Methods: The formalin-fixed paraffin-embedded breast tissue blocks of 125 patients with primary breastcarcinomas were subjected to immunohistochemical analysis using Ventana Benchmark® GX automated immunostainer.Analysis of variance and Chi-2 test were used to examine the relationship between Ki-67 and clinicopathologicvariables. Results: The mean age of 125 patients included in the study was 47.7 years. The average score of Ki-67was 56.0%. 84.8% of patients showed Ki-67 ≥ 14%. Mean scores of Ki-67 were correlated with grade (p = 0.006),PR (p = 0.026), histological type, ER, combined ER/RP, and molecular subtype (p < 0.001). Ki-67 was independentof HER2 (p = 0.402) and menopausal status (p = 0.471). The frequency of Ki-67 according to St Gallen 2011 wasassociated with histological type (p = 0.005), grade (p = 0.005), ER (p < 0.001), combined ER/PR (p = 0.004), andmolecular subtype (p = 0.004). There was no significant relationship between the distribution of Ki-67 and the age ofthe patients (p = 0.859), menopausal status (p = 0.979), PR (p = 0.149), and HER2 (p = 0.597). Conclusion: Ki-67 isuseful for treatment decisions in primary breast cancer patients. The high value of Ki-67 was associated with adverseclinicopathologic factors. The increased Ki-67 value should be carefully investigated in triple negative patients.Keywords
This publication has 29 references indexed in Scilit:
- Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory CoastBMC Cancer, 2017
- A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast CancerOncology, 2015
- Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trialAnnals of Oncology, 2013
- Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in LibyaJournal of Cancer, 2012
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatmentBMC Cancer, 2011
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast CancerJournal of Clinical Oncology, 2011
- MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroupsBreast Cancer Research and Treatment, 2010
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI Journal of the National Cancer Institute, 2009
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Ki67 immunostaining in primary breast cancer: pathological and clinical associationsBritish Journal of Cancer, 1989